CHEST 2023 On Demand Pass-Interstitial Lung Disease after Surviving COVID-19: An Update for 2023

Video Transcription

Video Summary

This video discusses interstitial lung disease (ILD) following COVID-19 infection and its implications for lung transplant. The presenter begins by highlighting the changes in the incidence and risk factors for developing post-COVID-19 ILD. They discuss the different types of ILD seen on CT scans and the likelihood of persistence of abnormalities after hospital discharge. The presenter then presents a case study of a patient who developed ILD after COVID-19 infection. They show CT scans and describe the various abnormalities seen. They also discuss the prevalence of ILD in post-COVID-19 patients, with studies showing that over 50% of patients still have abnormal CT scans six months after hospital discharge. They also discuss the risk factors for developing ILD, including disease severity, older age, longer hospital stay, hypertension, and smoking history. The presenter then shifts to the prognosis and treatment options for post-COVID-19 ILD. They highlight that most cases of ILD improve or stabilize, but a significant proportion of patients still have deficits in lung function. They discuss the potential preventive and treatment options, including antifibrotics and anti-inflammatory drugs. They also mention ongoing clinical trials in this area. In conclusion, the presenter emphasizes the need for precision-based approaches to post-COVID-19 ILD, considering the heterogeneity of the condition, and highlights the importance of collaborative care for these patients.

Meta Tag

Category Diffuse Lung Disease

Session ID 1082

Speaker Harpreet Grewal

Speaker Corey Kershaw

Speaker Claire McGroder

Track Diffuse Lung Disease

Keywords

interstitial lung disease

COVID-19 infection

lung transplant

CT scans

abnormalities

prognosis

treatment options

collaborative care